DE602007010108D1 - - Google Patents

Info

Publication number
DE602007010108D1
DE602007010108D1 DE602007010108T DE602007010108T DE602007010108D1 DE 602007010108 D1 DE602007010108 D1 DE 602007010108D1 DE 602007010108 T DE602007010108 T DE 602007010108T DE 602007010108 T DE602007010108 T DE 602007010108T DE 602007010108 D1 DE602007010108 D1 DE 602007010108D1
Authority
DE
Germany
Prior art keywords
determining
kits
subject
methods
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602007010108T
Other languages
English (en)
Inventor
Nadir Arber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MEDICAL RES FUND OF TEL AVIV S
Original Assignee
MEDICAL RES FUND OF TEL AVIV S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MEDICAL RES FUND OF TEL AVIV S filed Critical MEDICAL RES FUND OF TEL AVIV S
Publication of DE602007010108D1 publication Critical patent/DE602007010108D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
DE602007010108T 2006-01-31 2007-01-31 Active DE602007010108D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76337806P 2006-01-31 2006-01-31
PCT/IL2007/000122 WO2007088537A2 (en) 2006-01-31 2007-01-31 Methods and kits for early detection of cancer or predisposition thereto

Publications (1)

Publication Number Publication Date
DE602007010108D1 true DE602007010108D1 (de) 2010-12-09

Family

ID=38001788

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602007010108T Active DE602007010108D1 (de) 2006-01-31 2007-01-31

Country Status (12)

Country Link
US (1) US9394569B2 (de)
EP (1) EP1994410B1 (de)
JP (1) JP5091163B2 (de)
AT (1) ATE486285T1 (de)
DE (1) DE602007010108D1 (de)
DK (1) DK1994410T3 (de)
ES (1) ES2355388T3 (de)
IL (1) IL193097A (de)
PL (1) PL1994410T3 (de)
PT (1) PT1994410E (de)
SI (1) SI1994410T1 (de)
WO (1) WO2007088537A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2355388T3 (es) 2006-01-31 2011-03-25 Medical Research Fund Of Tel Aviv Sourasky Medical Center Métodos para la detección precoz de cáncer.
CA2703794C (en) * 2007-12-10 2017-03-21 The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center Methods of diagnosing cancer
CA2742324A1 (en) * 2008-10-30 2010-06-03 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Methods for assessing rna patterns
GB2463401B (en) 2008-11-12 2014-01-29 Caris Life Sciences Luxembourg Holdings S A R L Characterizing prostate disorders by analysis of microvesicles
CA2787027A1 (en) 2010-01-13 2011-07-21 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Detection of gastrointestinal disorders
CA2791905A1 (en) 2010-03-01 2011-09-09 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Biomarkers for theranostics
AU2011237669B2 (en) 2010-04-06 2016-09-08 Caris Life Sciences Switzerland Holdings Gmbh Circulating biomarkers for disease
AU2011256064B2 (en) 2010-05-21 2016-09-15 The Governors Of The University Of Alberta Methods for the assessment of colorectal cancer and colorectal polyps by measurement of metabolites in urine
US9953130B2 (en) * 2013-10-01 2018-04-24 Life Technologies Corporation Systems and methods for detecting structural variants
EP3652541B1 (de) * 2017-05-21 2022-12-14 The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center Kombination von markern zur diagnose von krebs
WO2019167047A1 (en) 2018-02-28 2019-09-06 The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center Methods of diagnosing and treating bladder cancer
MX2021006234A (es) 2018-11-30 2021-09-10 Caris Mpi Inc Perfilado molecular de proxima generacion.
CN110777213A (zh) * 2019-11-05 2020-02-11 武汉科技大学 一种潜伏期胃癌诊断试剂盒
EP4069865A4 (de) 2019-12-02 2023-12-20 Caris MPI, Inc. Platinresistenztest für pan-krebs
US11840720B2 (en) 2019-12-23 2023-12-12 Metabolomic Technologies Inc. Urinary metabolomic biomarkers for detecting colorectal cancer and polyps

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07500411A (ja) * 1991-02-05 1995-01-12 ファロク　セィディ 癌胎児性抗原を検出するための簡易検査法
US5741650A (en) * 1996-01-30 1998-04-21 Exact Laboratories, Inc. Methods for detecting colon cancer from stool samples
US7081516B2 (en) * 2002-08-26 2006-07-25 Case Western Reserve University Methods for categorizing patients
EP1497642A2 (de) 2002-03-19 2005-01-19 Tularik, Inc. Genamplifizierung bei krebs
US20040097448A1 (en) * 2002-11-19 2004-05-20 Isis Pharmaceuticals Inc. Modulation of CD24 expression
WO2005024603A2 (en) * 2003-09-10 2005-03-17 The Board Of Regents Of The University Of Texas System Methods for detecting, diagnosing and treating human renal cell carcinoma
EP1706507A4 (de) * 2003-11-26 2008-02-20 Univ Ohio State Res Found Das risiko und die progression von multipler sklerose vorhersagenden polymorphen cd24-genotypen
CA2453198A1 (en) 2004-01-07 2005-07-07 Wei-Ping Min Quantification and generation of immune suppressive exosomes
US7666583B2 (en) * 2004-02-19 2010-02-23 Yale University Identification of cancer protein biomarkers using proteomic techniques
ES2355388T3 (es) 2006-01-31 2011-03-25 Medical Research Fund Of Tel Aviv Sourasky Medical Center Métodos para la detección precoz de cáncer.

Also Published As

Publication number Publication date
US20100062450A1 (en) 2010-03-11
WO2007088537A2 (en) 2007-08-09
JP5091163B2 (ja) 2012-12-05
IL193097A0 (en) 2009-02-11
PL1994410T3 (pl) 2011-12-30
US9394569B2 (en) 2016-07-19
PT1994410E (pt) 2011-01-10
JP2009525041A (ja) 2009-07-09
ATE486285T1 (de) 2010-11-15
SI1994410T1 (sl) 2011-03-31
EP1994410B1 (de) 2010-10-27
DK1994410T3 (da) 2011-01-31
EP1994410A2 (de) 2008-11-26
ES2355388T3 (es) 2011-03-25
IL193097A (en) 2013-03-24
WO2007088537A3 (en) 2007-10-25

Similar Documents

Publication Publication Date Title
DE602007010108D1 (de)
MX2009012722A (es) Variantes geneticas sobre chr 5p12 y 10q26 como marcadores para el uso en la evaluacion del riesgo, diagnostico, pronostico y tratamiento del cancer de mama.
WO2004097052A3 (en) Methods for prognosis and treatment of solid tumors
WO2007089911A3 (en) Methods for detection of circulating tumor cells and methods of diagnosis of cancer in a mammalian subject
EP3831954A3 (de) Verfahren und zusammensetzungen zur molekularen profilierung für die diagnose von erkrankungen
WO2007102891A3 (en) Materials and methods for assaying for methylation of cpg islands associated with genes in the evaluation of cancer
WO2007053648A3 (en) Compositions and methods for treating and diagnosing cancer
WO2010004591A3 (en) Genetic variants for breast cancer risk assessment
WO2008016374A8 (en) Methods for assessing probabilistic measures of clinical outcome using genomic profiling
WO2010031056A3 (en) Methods and compositions for modulating ire1, src, and abl activity
WO2013022995A3 (en) Biomarker compositions and methods
WO2008117314A3 (en) Genetic variants on chr2 and chr16 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
WO2013022953A3 (en) Biomarker for alzheimer's disease and/or mild cognitively impairment, and use thereof
WO2008108803A3 (en) Immune cell biosensors and methods of using same
WO2006138275A3 (en) Compositions and methods for treating and diagnosing cancer
WO2006085984A3 (en) Immune cell biosensors and methods of using same
MX2009005651A (es) Marcadores geneticos para el manejo de riesgo de la arritmia cardiaca.
WO2006076025A3 (en) Immune cell biosensors and methods of using same
WO2009064789A3 (en) Methods for detecting and monitoring circulating cancer stem cells
WO2006059252A3 (en) Methods and fluorinated compositions for treating amyloid-related diseases
WO2008088860A3 (en) Polymorphisms in the egfr pathway as markers for cancer treatment
DE502005008373D1 (de) Polymorphismen im nod2/card15 gen
WO2007103816A3 (en) Polymorphisms in voltage-gated sodium channel alpha 1-subunit as markers for therapy selection
WO2007006862A3 (en) Method and kit for detecting a risk of coronary heart disease
WO2006099259A3 (en) Novel missense mutations and single nucleotide polymorphisms in the rabphillin-3a-like gene and uses thereof